ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

Company Overview - ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on empowering at-risk patients and caregivers to protect against severe allergic reactions that could lead to anaphylaxis [3] - The company is commercializing neffy 2 mg (trade name EURneffy in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30 kg or greater [3] Upcoming Events - Richard Lowenthal, Co-Founder, President and CEO, along with Eric Karas, Chief Commercial Officer, will participate in a fireside chat on February 12, 2025, at 2:40 p.m. ET during the Oppenheimer 35th Annual Healthcare Conference [2] - The company management will also engage in one-on-one meetings with investors, and a live webcast of the fireside chat will be available on the company's website [2]